Virginia Powers, PhD

Articles

Ribociclib Emerges as Option for Elderly Patients with HR+/HER2- Breast Cancer

February 07, 2017

The clinical benefits and safety profiles for ribociclib remained consistent when treating both younger and elderly patients with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced breast cancer.